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Laboratory investigations corroborating 
the diagnosis of PNH includes the presence 
of hemoglobinuria, a peripheral blood smear 
demonstrating red blood cell fragments and 
an elevated lactate dehydrogenase assay [4]. 
Clinical diagnosis of PNH may be con-
firmed with peripheral blood flow cytom-
etry demonstrating the absence or severe 
deficiency of GPI-anchored proteins on at 
IntroduCtIon
Paroxysmal nocturnal hemoglobinuria is 
a rare disease and the estimated prevalence 
of this disorder is in the range of one to ten 
cases per million population with estimates 
in the pregnant population being limited to 
case report data [1]. The median age of on-
set of PNH is in the mid-thirties and can 
affect women of childbearing age and in 
some instances PNH may be diagnosed in 
pregnancy for the first time [1,2]. There is 
no demonstrable ethnic or geographic dis-
tribution of the disease [1].
PNH represents the clonal expansion of he-
matopoietic stem cells that have an acquired 
somatic mutation in the phosphatidylinositol 
glycan-complementation class A (PIG-A) 
gene with a consequent deficiency of glycosyl 
phosphatidylinositol-anchored proteins in-
cluding the complement-regulatory proteins 
CD55 and CD59. The clinical sequelae of the 
deficiency of these complement-regulatory 
proteins renders affected cells susceptible to 
lysis mediated via complement [3].
Why Do We Describe This Case
This case highlights a rare disease with a 
prevalence of 1-2 cases per million people 
with data on the existence of this disease 
in the gravid population being limited to 
case report data. The rarity of this con-
dition in the general population and in 
maternal medicine poses a dilemma for 
available therapeutic options and this 
case demonstrates the lack of availability 
of drugs such as eculizumab in resource-
limited countries
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Case report
Abstract
Paroxysmal Nocturnal Hemoglobinuria (PNH) originates from an acquired genetic defect in a 
multipotent hematopoietic stem cell that becomes stem-cell-like in its ability to survive, expand, 
and self-renew. PNH is a rare condition characterized by intravascular hemolysis. PNH can 
arise anew or in the setting of an underlying bone marrow disorder such as aplastic anemia 
(AA), myelodysplastic syndrome (MDS), or primary myelofibrosis (PMF).
This case presentation documents the challenging diagnosis of PNH in the obstetric setting, in 
which other possible causes for a hemolytic anemia could be considered. We discuss the management 
of a pregnancy in the presence of PNH in a low-to-middle income setting.
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of malaria. Limited workup for the anemia 
had been performed in Malawi and a tenta-
tive diagnosis of a suspected aplastic anemia 
was made.
Vital signs recorded in Table I revealed a 
resting tachycardia with other vitals being 
within normal limits. Urine dipsticks re-
vealed trace proteinuria and 1+ blood (weak 
positivity for blood).
General examination of our patient was 
unremarkable except for the presence of 
conjunctival rim pallor and non-pitting 
pedal edema.
Systems examination revealed a resting 
tachycardia with a left parasternal border 
systolic murmur. Abdominal examination 
revealed a palpable gravid uterus with the 
height of the uterine fundus at 14 cm. There 
was no palpable lymphadenopathy and no 
hepatosplenomegaly. Examination of the 
musculoskeletal system did not demonstrate 
any discrepancy in the diameter of the calves.
Blood tests revealed low levels of: white 
cell count, hemoglobin, and serum iron 
(Table II).
Elevated levels of mean cell volume, red 
cell distribution width, total and direct/con-
jugated bilirubin, aspartate transaminase, fi-
brinogen, and D-dimers were also detected 
(Table II).
The smear showed the presence of scanty 
red blood cell fragments.
Bone marrow aspirate demonstrated fea-
tures of a megaloblastosis which may be in 
keeping with chronic hemolysis. Overall 
bone marrow aspirate revealed marked hy-
percellularity with normal lymphocyte mor-
phology. The bone marrow aspirate did not 
reveal any features of plasmacytosis with no 
other foreign cells noted.
Vital Signs Value
Blood pressure (mmHg) 104/76
Heart rate (beats per minute) 121
Respiratory rate (breaths per minute) 13
Oral temperature (degrees Celsius) 37.2
Oxygen saturation (pulse oximetry %) 95
Finger-prick glucose (mmol/L) 5.3
table I. Vital signs.
Investigation result normal range
White cell count (× 109/L) 2.39 3.9-12.6
Hemoglobin (g/dL) 4.9 11.6-16.4
Mean cell volume (fL) 105.6 76-100
Mean cell hemoglobin (pg) 29.3 26.1-33.5
Red cell distribution width (%) 23.1 12.4-17.3
Platelets (× 109/L) 249 186-454
Smear Scanty RBC fragments
C-Reactive Protein (mg/L) 9 <10
Total bilirubin (µmol/L) 30 5-21
Direct/conjugated bilirubin (µmol/L) 5 0-3
Alanine transaminase (U/L) 14 7-35
Aspartate transaminase (U/L) 106 13-35
International normalized ratio (INR) 1.01 ≤1.1
Fibrinogen (g/L) 4.3 2-4
D-dimers (mg/L) 5.24 0-0.25
Serum iron (µmol/L) 5.0 8-252
Serum ferritin (µg/L) 22 22-265
table II. Basic 
investigations.
RBC = red blood cells
C5 protein terminal, which reduces erythro-
cytic cellular lysis and stabilizes the plasma 
hemoglobin levels [6].
Eculizumab is the only drug approved 
for the treatment of PNH in USA, EU, 
and several other countries. It is currently 
not available in South Africa for the treat-
ment of PNH.
CASe PreSentAtIon
Miss AP was a 25-year-old female who 
was born in Malawi and had re-located to 
South Africa with her husband one year 
prior to consultation by the internal medi-
cine service at Kalafong Tertiary Hospital. 
She was a primigravida and had a normal 
antenatal record except for the presence of a 
low hemoglobin. Other than her re-location 
to South Africa, our patient had no recent 
travel history to a malaria endemic area 
within South Africa.
At the time of consultation Miss AP had 
an estimated gestational age of 14 weeks 
with the initial consultation from the Ob-
stetric service being for the establishment of 
the route cause of Miss AP’s anemia.
Miss AP had been previously diagnosed 
with an anemia in Malawi for which she 
recalls numerous admissions for blood 
transfusions and specifically recalls receiv-
ing transfusions of PRBCs during bouts 
least two cell lines. The detection of GPI-
anchored proteins may be performed by la-
belling cells with monoclonal antibodies or 
a fluorescein-tagged proaerolysin (FLAER) 
reagent [4]. Bone marrow biopsy is not usu-
ally indicated in most cases.
Pregnancy is generally discouraged in 
patients with PNH due to the high risk of 
both fetal and maternal mortality. Anemia 
in a pregnant patient with PNH is some-
times more severe and more frequent trans-
fusions of packed red blood cells (PRBCs) 
are required [5]. Owing to the occurrence 
of thrombosis in up to 40% of patients with 
PNH, the administration of low-molecular-
weight heparin (LMWH) is advised [1]. 
LMWH is generally administered from the 
time of confirmation of pregnancy to the end 
of the postpartum period [5].
Eculizumab is a humanized monoclonal 
antibody directed against the complement 
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Parvovirus B19 polymerase chain reaction 
performed on peripheral blood was negative.
Hemolysis specific investigations detected 
elevated levels of lactate dehydrogenase and 
low levels of haptoglobin (Table III).
FLAER test and flow cytometry detected 
the presence of a PNH clone.
Table IV shows the PNH panel. The ex-
pression of the GPI anchored proteins, 
CD55 (DAF) and CD59 (MIRL) was ab-
normal on both neutrophils and erythro-
cytes. Expression of the GPI-linked proteins 
(CD14 on monocytes and CD16 on neu-
trophils) was normal. In summary, there was 
phenotypic evidence of PNH based on 
analysis of a variety of GPI-linked antibod-
ies on red blood cells and granulocytes.
A diagnosis of classical PNH was made 
after systematically excluding other probable 
causes of a process of intravascular hemoly-
sis. Miss AP was referred from her antenatal 
clinic at Kalafong Tertiary Hospital to the 
Obstetric service at Steve Biko Academic 
Hospital. She was jointly managed by Ob-
stetric Medicine, Maternal Fetal Medicine 
as well as the Hematology Service. She de-
clined termination of pregnancy after care-
ful counselling about a guarded prognosis. 
Miss AP was commenced on enoxaparin 
(LMWH) from time of diagnosis (16 weeks) 
Investigation result normal range
Malaria antigen/smear Negative
Anti-nuclear antibodies Negative
Extractable Nuclear Antigen Negative
Direct antibody testing (Coombs) Negative
Lactate dehydrogenase (U/L) 2673 208-378
Haptoglobin (g/L) 0.07 0.3-2.0
Hemoglobin electrophoresis No abnormal hemoglobin variant
Glucose-6-phosphate dehydrogenase levels Normal
Vitamin B12 levels (pmol/L) 484 133-675
Serum folate levels (nmol/L) 55 7.0-45.1
Urine hemosiderin Positive
FLAER test and flow cytometry PNH clone present
table III. Hemolysis 
specific investigations.
Cell Line PnH Clone (percent %)
CD55- erythrocytes 11
CD59- erythrocytes 11
CD14- monocytes 0.0
CD55- granulocytes 71
table IV. PNH panel 
(National Health 
Laboratory Service—
NHLS, South Africa).
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two entities may show overlap in symptom-
atology (i.e. nausea, abdominal discomfort) 
and abnormal laboratory findings of intra-
vascular hemolysis (elevated lactate dehy-
drogenase, elevated unconjugated bilirubin, 
low haptoglobin, and low platelet count) [2].
PNH in pregnancy is associated with 
increased risks of complications such as 
thromboembolic diseases (e.g. Budd-Chi-
ari syndrome), hypertensive disorders like 
preeclampsia, and cerebrovascular diseases. 
PNH in pregnancy can cause significant feto-
maternal morbidity and mortality with the 
estimated maternal mortality ranging from 
5.8% to 20.8%. More than 45% of pregnan-
cies in women with PNH result in either 
spontaneous miscarriage or termination. Of 
the women who give birth, more than half 
deliver prematurely, an event that can have 
negative implications for the health of the 
new-born baby [3,5].
Eculizumab is a humanized monoclonal 
antibody that binds to the complement pro-
tein C5 and blocks terminal complement 
activation. During pregnancy eculizumab has 
shown a low rate of maternal complications 
up to now. However, expertise in managing 
pregnant patients with PNH with eculizumab 
is limited. In fact, prospective trials are unlike-
ly to be initiated, due to the rarity of the dis-
ease. The drug is still listed in pregnancy as a 
category C drug («animal reproduction stud-
ies have shown an adverse effect on the fetus 
and there are no adequate and well-controlled 
studies in humans, but potential benefits may 
warrant use of the drug in pregnant women 
despite potential risks» [7]), but potential 
benefits may outweigh potential risks [5]. The 
cost of eculizumab, trade name Soliris®, is ap-
proximately 18,000 USD per dose, making it 
one of the most expensive drugs in the United 
States [8]. The exorbitant cost of the drug 
makes its use in PNH in resource-constrained 
countries almost unjustified.
Key Points
 y PNH is a rare acquired disease with an estimated incidence of 1 to 5 cases per million 
individuals
 y The exact incidence of PNH in pregnancy is unknown as only case report data on the 
condition exist
 y PNH results in intravascular hemolysis and other conditions in pregnancy causing hemo-
lysis also require consideration as diagnoses
 y Thrombosis is one of the most feared complications of PNH in pregnancy as it can result 
in fetal loss as well as significant maternal morbidity/mortality
 y Standard of care for patients in resource-limited settings is mainly supportive with the use 
of hematinics and with the appropriate transfusion of blood products
until the birth of her infant at 37 weeks. As 
the post-natal period in PNH is associated 
with a high incidence of thrombosis, she 
was placed on warfarin for 3 months post-
delivery. Miss AP was supported during her 
pregnancy with folic acid and other hema-
tinics, as well as transfusions of packed red 
blood cells when her hemoglobin dropped 
below 7g/dL. Miss AP had an uneventful 
pregnancy with no episodes of thrombosis 
and delivered a live male baby via spontane-
ous vaginal delivery at 37 weeks.
dISCuSSIon
PNH or Paroxysmal Nocturnal Hemo-
globinuria is a rare disease entity which has 
a prevalence of 1-2 cases per million people 
[1]. The disease has a slight female prepon-
derance and women of child-bearing poten-
tial are also affected [2]. The exact incidence 
of PNH in pregnancy is unknown and only 
case report data on PNH in pregnancy exists.
PNH is a non-neoplastic human dis-
ease caused by a somatic mutation of the 
X-linked phosphatidylinositol glycan-
complementation class A gene in hemato-
poietic stem cells which makes red blood 
cells more vulnerable to lysis mediated by 
complement [1,2].
The long-term complications of PNH 
include a chronic intravascular hemolysis 
complicated by anemia, venous thromboem-
bolism as well as bone marrow failure [1,4].
The clinical diagnosis of PNH in the set-
ting of an obstetric patient can be a diag-
nostic challenge as the range of signs and 
symptoms present can be confounded with 
various pregnancy complications like pre-
eclampsia, HELLP syndrome or pregnan-
cy-associated thrombocytopenia. It is par-
ticularly important to try and distinguish a 
HELLP syndrome from a PNH crisis as the 
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